Login to Your Account



MacroGenics' DART Platform Grabs Potential $1B Gilead Deal

By Randy Osborne
Staff Writer

Tuesday, January 8, 2013
Almost nine months of talks gave birth to the potential $1 billion deal disclosed Monday morning by MacroGenics Inc., which will deploy the company's Dual‐Affinity Re‐Targeting (DART) technology for drugs directed at up to four targets in an agreement with Gilead Sciences Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription